Clinical Trials

200 enrolled 12 charts

Multiple Myeloma

NCT04133636 2026-04-13

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT04623541 2026-04-13

EPCORE™ CLL-1

LymphoidOther hematologic neoplasm

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04722146 2026-04-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04923893 2026-04-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05050097 2026-04-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT06577025 2026-04-13

aMMbition

43 enrolled

Multiple Myeloma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 3 FDA

Multiple Myeloma

NCT04542824 2026-04-08

EPCORE™ NHL-3

LymphoidOther hematologic neoplasm

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05660967 2026-04-08

EPCORE DLBCL-3

111 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05888493 2026-03-24

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

237 enrolled

Phase 4 Active not recruiting

Lymphoma, Follicular

NCT03173092 2026-03-18

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

141 enrolled

Multiple Myeloma

NCT04404283 2026-03-17

ECHELON-3

238 enrolled 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT06045806 2026-03-05

KarMMa-9

79 enrolled

Multiple Myeloma

NCT05090566 2026-02-23

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

46 enrolled 15 charts

Multiple Myeloma

NCT04712097 2026-02-04

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT05222555 2026-01-16

MINDway

53 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT04680052 2025-12-22

InMIND

654 enrolled 40 charts 3 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT04661007 2025-12-18

J-MIND

72 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

337 enrolled

Multiple Myeloma

NCT05429268 2025-12-10

firmMIND

82 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04091126 2025-11-28

DREAMM 9

118 enrolled

Multiple Myeloma

NCT03106324 2025-11-24

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Active not recruiting

911 enrolled

Multiple Myeloma

NCT04126200 2025-11-06

DREAMM5

208 enrolled

Multiple Myeloma

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

113 enrolled 19 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT05371093 2025-10-15

ZUMA-22

231 enrolled

Lymphoma, Follicular

NCT07150091 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

20 enrolled

Multiple Myeloma

NCT05308654 2025-08-14

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

34 enrolled

Multiple Myeloma, Neoplasms

NCT05409066 2025-07-28

EPCORE FL-1

549 enrolled 5 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT05669989 2025-01-23

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Multiple Myeloma

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

73 enrolled

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT05201248 2025-01-07

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

49 enrolled

Neoplasms, Lymphoma, B-Cell

NCT03319667 2024-11-27

IMROZ

475 enrolled 3 FDA

Multiple Myeloma

NCT03651128 2022-12-15

KarMMa-3

381 enrolled